Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease

Sponsored by Composite Interceptive Med Science

About this trial

Last updated 8 years ago

Study ID

OI-009-2018

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Started 8 years ago

What is this trial about?

Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.

What are the participation requirements?

Inclusion Criteria

Adults aged over 18 years with the evidence of alcoholic liver disease (ALD) based on a thorough history, physical examination, and laboratory tests and all of the following: * Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire * Active alcohol use until 4 weeks prior to presentation * ALT and AST elevated >1.5 times the upper limit of normal * Over 1.5 ratio of AST to ALT * Maddrey Discriminant function(DF) less than 30

Exclusion Criteria

* Severe alcoholic hepatitis with cirrhosis or life expectancy less than 3 months * Severe renal impairment (Glomerular filtration rate below 60 ml/min per 1.73m2) * Hepatic disorders due to cardiac causes, inherited metabolic causes, hemochromatosis and Wilson's disease * Participants with active viral hepatitis * Under going active treatment for alcohol withdrawal syndrome(AWS) at the study entry * Participants on hepatotoxic medications like antitubercular medication, antiviral medication, paracetamol etc. * Pregnant, attempting to conceive, or lactating women * Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.